BEGIN:VCALENDAR VERSION:2.0 PRODID:-//Sabre//Sabre VObject 4.6.1//EN CALSCALE:GREGORIAN BEGIN:VTIMEZONE TZID:Europe/Zurich X-LIC-LOCATION:Europe/Zurich TZURL:http://tzurl.org/zoneinfo/Europe/Zurich BEGIN:DAYLIGHT TZOFFSETFROM:+0100 TZOFFSETTO:+0200 TZNAME:CEST DTSTART:19810329T020000 RRULE:FREQ=YEARLY;BYMONTH=3;BYDAY=-1SU END:DAYLIGHT BEGIN:STANDARD TZOFFSETFROM:+0200 TZOFFSETTO:+0100 TZNAME:CET DTSTART:19961027T030000 RRULE:FREQ=YEARLY;BYMONTH=10;BYDAY=-1SU END:STANDARD END:VTIMEZONE BEGIN:VEVENT UID:news815@chemie.unibas.ch DTSTAMP;TZID=Europe/Zurich:20261026T152351 DTSTART;TZID=Europe/Zurich:20261119T170000 SUMMARY:Overcoming the Undruggable Nature of the Most Common Human Oncogene \, K-Ras (Camille & Henry Dreyfus Lecture 2026) DESCRIPTION:Since the discovery of the first human oncogene\, KRAS\, in the early 1980s there has been an explosion in our understanding of cancer. D rugs targeting other oncogenes such as the protein kinase BCR-ABL which ca uses a type of blood cancer have profoundly affected the lives of cancer p atients since the approval of imatinib in 1999. While the pace of discover y of drugs which target certain classes of oncoproteins (protein kinases i n EGFR driven lung cancer and nuclear hormone receptors in breast and pros tate cancer) have been remarkable\, the cancers driven by the GTPase\, KRA S\, have been slower to develop because the K-Ras protein lacked obvious d rug binding pockets. I will discuss the challenges faced by academic and i ndustry scientists which led to the notion that K-Ras was “undruggable ”.\\r\\nIn 2013 our laboratory reported the first drug binding pocket on K-Ras (G12C) which was followed eight years later by the FDA approval of sotorasib and adagrasib. The current challenge of developing drugs for oth er even more common K-Ras mutants such as K-Ras (G12D) will be discussed i ncluding current agents in clinical trials as well as how to leverage the immune system to further attack K-Ras mutant driven lung\, colon and pancr eatic cancer.\\r\\n\\r\\nCamille & Henry Dreyfus LectureshipIn memory of t he Dreyfus brothers\, the Camille and Henry Dreyfus Foundation Inc. has es tablished the Camille & Henry Dreyfus Lectureship at the University of Bas el [https://chemie.unibas.ch/de/aktuelles/veranstaltungen/dreyfus-lectures hip/]. The annual Lectureship brings a leading chemist from the United Sta tes to the Basel campus to deliver a series of talks\, and to meet with fa culty and students in order to enhance the relationship between Swiss and U.S. science. X-ALT-DESC:

Since the discovery of the first human oncogene\, KRAS\, in t he early 1980s there has been an explosion in our understanding of cancer. Drugs targeting other oncogenes such as the protein kinase BCR-ABL which causes a type of blood cancer have profoundly affected the lives of cancer patients since the approval of imatinib in 1999. While the pace of discov ery of drugs which target certain classes of oncoproteins (protein kinases in EGFR driven lung cancer and nuclear hormone receptors in breast and pr ostate cancer) have been remarkable\, the cancers driven by the GTPase\, K RAS\, have been slower to develop because the K-Ras protein lacked obvious drug binding pockets. I will discuss the challenges faced by academic and industry scientists which led to the notion that K-Ras was “undruggable ”.

\n

In 2013 our laboratory reported the first drug binding pocket on K-Ras (G12C) which was followed eight years later by the FDA approval of sotorasib and adagrasib. The current challenge of developing drugs for other even more common K-Ras mutants such as K-Ras (G12D) will be discusse d including current agents in clinical trials as well as how to leverage t he immune system to further attack K-Ras mutant driven lung\, colon and pa ncreatic cancer.

\n\n

Camille &\; Henry Dreyfus Lectureshi p
In memory of the Dreyfus brothers\, the Camille and Henry Dreyfus Foundation Inc. has established the Cam ille &\; Henry Dreyfus Lectureship at the University of Basel. The annual Lectureship brings a leading chemist from the United States to the Basel campus to deliver a series of talks\, and to meet with faculty and s tudents in order to enhance the relationship between Swiss and U.S. scienc e.

DTEND;TZID=Europe/Zurich:20261119T183000 END:VEVENT END:VCALENDAR